

December 22, 2025
SymBio Pharmaceuticals Limited
Fuminori Yoshida
Representative Director
President and Chief Executive Officer
(Securities Code: 4582)

**SymBio Receives Notice of Allowance in the U.S. for IV BCV Use Patent,
Securing Exclusivity Through 2044**

Tokyo, Japan, December 22, 2025 – SymBio Pharmaceuticals Limited (hereinafter “SymBio” or the “Company”) today announced that it has received a Notice of Allowance from the United States Patent and Trademark Office for a new use patent covering intravenous brincidofovir (IV BCV) for the treatment of adenovirus infection. Upon issuance, the patent will confer protection in the United States through 2044. In Japan, the corresponding patent has already been granted and is valid through 2043. Examination in Europe is ongoing.

The allowed claims cover clinical use parameters, including dosing and administration of IV BCV for adenovirus infection following hematopoietic stem cell transplantation, as evaluated in the Company’s ongoing clinical study. The patent is intended to protect appropriate use information anticipated post-approval (including elements to be reflected in the package insert) and is expected to afford strong legal protection. Consequently, in both the U.S. and Japan, the period of protection for IV BCV is expected to extend beyond the formulation patent. In addition, IV BCV has received Orphan Drug Designation for adenovirus in Japan and Europe, providing 10 years of regulatory exclusivity following launch.

SymBio will continue to secure indication-specific use patents aligned with real-world clinical practice (including elements reflected in the package insert) to extend and strengthen exclusivity by indication and maximize the asset value of IV BCV.

SymBio remains committed to accelerating development and commercialization of BCV to bring it to patients as quickly as possible and address critical unmet medical needs.

[Contact] Investor Relations Tel: +81(0)3 5472 1125

Note

Overview of Use Patent for IV BCV in Adenovirus (for which a Notice of Allowance has been received)

Patent holder: SymBio Pharmaceuticals Limited

Term of validity:

- Japan: August 7, 2043 (Patent No. 7,417,339)
- U.S.: May 6, 2044 (expected)

Scope: Clinical regimen (dosing and administration) of IV BCV for the treatment of adenovirus infection

Overview of Formulation Patents for IV BCV

Jurisdictions and patent numbers:

- Japan (Patent Nos. 6,878,473; 7,221,485; 7,407,984)
- Europe (Patent No. 3,474,822)
- U.S. (Patent No. 12,485,131)

Patent holder: Emergent Biodefense Operations Lansing LLC

Term of validity: June 28, 2037

Scope: Formulation of intravenous brincidofovir for IV administration

BCV Business Strategy Based on Three Therapeutic Pillars

Since obtaining the global license for BCV in September 2019, SymBio has advanced collaborative research with world-class institutions to unlock its potential across three therapeutic areas. We are currently focusing our development resources on: (1) viral infections following hematopoietic stem cell transplantation; (2) hematologic and solid tumors; and (3) neurodegenerative diseases. By pursuing development and commercialization globally across these three pillars, SymBio aims to maximize the value of the BCV franchise. To date, the Company has filed for eight patents, and by layering these IP initiatives with regulatory strategies such as Orphan Drug Designation, SymBio aims to maximize the value of our pipeline.